Literature DB >> 12885879

Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.

L Jean Patterson1, Nina Malkevitch, Joel Pinczewski, David Venzon, Yuanmei Lou, Bo Peng, Cindy Munch, Melissa Leonard, Ersell Richardson, Kristine Aldrich, V S Kalyanaraman, George N Pavlakis, Marjorie Robert-Guroff.   

Abstract

Immunity elicited by multicomponent vaccines delivered by replication-competent Ad5hr-simian immunodeficiency virus (SIV) recombinants was systematically investigated. Rhesus macaques were immunized mucosally at weeks 0 and 12 with Ad5hr-SIV(smH4) env/rev, with or without Ad5hr-SIV(mac239) gag or Ad5hr-SIV(mac239) nef, or with all three recombinants. The total Ad5hr dosage was comparably adjusted among all animals with empty Ad5hr-DeltaE3 vector. The macaques were boosted with SIV gp120 in monophosphoryl A-stable emulsion adjuvant at 24 and 36 weeks. Controls received Ad5hr-DeltaE3 vector or adjuvant only. By ELISPOT analysis, all four SIV gene products elicited potent cellular immune responses that persisted 42 weeks post-initial immunization. Unexpectedly, modulation of this cellular immune response was observed among macaques receiving one, two, or three Ad5hr-SIV recombinants. Env responses were significantly enhanced throughout the immunization period in macaques immunized with Ad5hr-SIV env/rev plus Ad5hr-SIV gag and tended to be higher in macaques that also received Ad5hr-SIV nef. Macaques primed with all three recombinants displayed significant down-modulation in numbers of gamma interferon (IFN-gamma)-secreting cells specific for SIV Nef, and the Env- and Gag-specific responses were also diminished. Modulation of antibody responses was not observed. Down-modulation was seen only during the period of Ad5hr-recombinant priming, not during subunit boosting, although SIV-specific IFN-gamma-secreting cells persisted. The effect was not attributable to Ad5hr replication differences among immunization groups. Vaccine delivery via replication-competent live vectors, which can persistently infect new cells and continuously present low-level antigen, may be advantageous in overcoming competition among complex immunogens for immune recognition. Effects of current multicomponent vaccines on individual immune responses should be evaluated with regard to future vaccine design.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12885879      PMCID: PMC167211          DOI: 10.1128/jvi.77.16.8607-8620.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Importance of the nef gene for maintenance of high virus loads and for development of AIDS.

Authors:  H W Kestler; D J Ringler; K Mori; D L Panicali; P K Sehgal; M D Daniel; R C Desrosiers
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

2.  The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus.

Authors:  D A Regier; R C Desrosiers
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

3.  High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants.

Authors:  P K Chanda; R J Natuk; B B Mason; B M Bhat; L Greenberg; S K Dheer; K L Molnar-Kimber; S Mizutani; M D Lubeck; A R Davis
Journal:  Virology       Date:  1990-04       Impact factor: 3.616

4.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

5.  Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant.

Authors:  S M Cheng; S G Lee; M Ronchetti-Blume; K P Virk; S Mizutani; J W Eichberg; A Davis; P P Hung; V M Hirsch; R M Chanock
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

7.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees.

Authors:  R J Natuk; M D Lubeck; P K Chanda; M Chengalvala; M S Wade; S C Murthy; J Wilhelm; S K Vernon; S K Dheer; S Mizutani
Journal:  AIDS Res Hum Retroviruses       Date:  1993-05       Impact factor: 2.205

9.  Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.

Authors:  R J Natuk; P K Chanda; M D Lubeck; A R Davis; J Wilhelm; R Hjorth; M S Wade; B M Bhat; S Mizutani; S Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

10.  Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs.

Authors:  M Chengalvala; M D Lubeck; A R Davis; S Mizutani; K Molnar-Kimber; J Morin; P P Hung
Journal:  Vaccine       Date:  1991-07       Impact factor: 3.641

View more
  26 in total

1.  Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus.

Authors:  Amitinder Kaur; Hannah B Sanford; Deirdre Garry; Sabine Lang; Sherry A Klumpp; Daisuke Watanabe; Roderick T Bronson; Jeffrey D Lifson; Margherita Rosati; George N Pavlakis; Barbara K Felber; David M Knipe; Ronald C Desrosiers
Journal:  Virology       Date:  2006-09-07       Impact factor: 3.616

2.  A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Thorsten Demberg; Ruth H Florese; Megan J Heath; Kay Larsen; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; David Venzon; Richard Grant; L Jean Patterson; Birgit Korioth-Schmitz; Adam Buzby; Dilani Dombagoda; David C Montefiori; Norman L Letvin; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

3.  Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.

Authors:  Ruth H Florese; Roger W Wiseman; David Venzon; Julie A Karl; Thorsten Demberg; Kay Larsen; Leon Flanary; V S Kalyanaraman; Ranajit Pal; Fausto Titti; L Jean Patterson; Megan J Heath; David H O'Connor; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  Vaccine       Date:  2008-04-30       Impact factor: 3.641

4.  Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route.

Authors:  L Jean Patterson; Seraphin Kuate; Mara Daltabuit-Test; Qingsheng Li; Peng Xiao; Katherine McKinnon; Janet DiPasquale; Anthony Cristillo; David Venzon; Ashley Haase; Marjorie Robert-Guroff
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

5.  Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.

Authors:  Rachmat Hidajat; Seraphin Kuate; David Venzon; Vaniambadi Kalyanaraman; Irene Kalisz; James Treece; Ying Lian; Susan W Barnett; Marjorie Robert-Guroff
Journal:  Vaccine       Date:  2010-04-09       Impact factor: 3.641

6.  Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge.

Authors:  L Jean Patterson; Mara Daltabuit-Test; Peng Xiao; Jun Zhao; William Hu; Ulrike Wille-Reece; Egidio Brocca-Cofano; V S Kalyanaraman; Irene Kalisz; Stephen Whitney; Eun Mi Lee; Ranajit Pal; David C Montefiori; Satya Dandekar; Robert Seder; Mario Roederer; Roger W Wiseman; Vanessa Hirsch; Marjorie Robert-Guroff
Journal:  Virology       Date:  2011-01-14       Impact factor: 3.616

7.  Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS.

Authors:  Monica Vaccari; Rabih Halwani; L Jean Patterson; Adriano Boasso; Jennifer Beal; Elzbieta Tryniszewska; Anna Hryniewicz; David Venzon; Elias K Haddad; Mohamed El-Far; Margherita Rosati; George N Pavlakis; Barbara K Felber; Saleh Al-Muhsen; Marjorie Robert-Guroff; Rafick-Pierre Sekaly; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

8.  Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques.

Authors:  Thorsten Demberg; Egidio Brocca-Cofano; Seraphin Kuate; Stanley Aladi; Diego A Vargas-Inchaustegui; David Venzon; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; Janet DiPasquale; Ruth M Ruprecht; David C Montefiori; Indresh Srivastava; Susan W Barnett; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-03-22       Impact factor: 3.616

9.  Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.

Authors:  Michael G Berg; Robert J Adams; Ratish Gambhira; Mark C Siracusa; Alan L Scott; Richard B S Roden; Gary Ketner
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

Review 10.  Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.

Authors:  L Jean Patterson; Marjorie Robert-Guroff
Journal:  Expert Opin Biol Ther       Date:  2008-09       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.